Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Increased Immune Activation by Pathologic α-Synuclein in Parkinson's Disease.

Grozdanov V, Bousset L, Hoffmeister M, Bliederhaeuser C, Meier C, Madiona K, Pieri L, Kiechle M, McLean PJ, Kassubek J, Behrends C, Ludolph AC, Weishaupt JH, Melki R, Danzer KM.

Ann Neurol. 2019 Oct;86(4):593-606. doi: 10.1002/ana.25557. Epub 2019 Aug 15.

PMID:
31343083
2.

Transmission of α-synuclein-containing erythrocyte-derived extracellular vesicles across the blood-brain barrier via adsorptive mediated transcytosis: another mechanism for initiation and progression of Parkinson's disease?

Matsumoto J, Stewart T, Sheng L, Li N, Bullock K, Song N, Shi M, Banks WA, Zhang J.

Acta Neuropathol Commun. 2017 Sep 13;5(1):71. doi: 10.1186/s40478-017-0470-4.

3.

Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.

Williams GP, Schonhoff AM, Jurkuvenaite A, Thome AD, Standaert DG, Harms AS.

J Neuroinflammation. 2018 Aug 30;15(1):244. doi: 10.1186/s12974-018-1286-2.

4.

Protein kinase Cδ upregulation in microglia drives neuroinflammatory responses and dopaminergic neurodegeneration in experimental models of Parkinson's disease.

Gordon R, Singh N, Lawana V, Ghosh A, Harischandra DS, Jin H, Hogan C, Sarkar S, Rokad D, Panicker N, Anantharam V, Kanthasamy AG, Kanthasamy A.

Neurobiol Dis. 2016 Sep;93:96-114. doi: 10.1016/j.nbd.2016.04.008. Epub 2016 May 2.

5.

Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein.

Watson MB, Richter F, Lee SK, Gabby L, Wu J, Masliah E, Effros RB, Chesselet MF.

Exp Neurol. 2012 Oct;237(2):318-34. doi: 10.1016/j.expneurol.2012.06.025. Epub 2012 Jun 27.

6.

Inhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.

Qin H, Buckley JA, Li X, Liu Y, Fox TH 3rd, Meares GP, Yu H, Yan Z, Harms AS, Li Y, Standaert DG, Benveniste EN.

J Neurosci. 2016 May 4;36(18):5144-59. doi: 10.1523/JNEUROSCI.4658-15.2016.

7.

Toll-like receptor expression in the blood and brain of patients and a mouse model of Parkinson's disease.

Drouin-Ouellet J, St-Amour I, Saint-Pierre M, Lamontagne-Proulx J, Kriz J, Barker RA, Cicchetti F.

Int J Neuropsychopharmacol. 2014 Dec 7;18(6). pii: pyu103. doi: 10.1093/ijnp/pyu103.

8.

Accelerated accumulation of retinal α-synuclein (pSer129) and tau, neuroinflammation, and autophagic dysregulation in a seeded mouse model of Parkinson's disease.

Mammadova N, Summers CM, Kokemuller RD, He Q, Ding S, Baron T, Yu C, Valentine RJ, Sakaguchi DS, Kanthasamy AG, Greenlee JJ, Heather West Greenlee M.

Neurobiol Dis. 2019 Jan;121:1-16. doi: 10.1016/j.nbd.2018.09.013. Epub 2018 Sep 12.

PMID:
30218757
9.

Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies.

Stuendl A, Kunadt M, Kruse N, Bartels C, Moebius W, Danzer KM, Mollenhauer B, Schneider A.

Brain. 2016 Feb;139(Pt 2):481-94. doi: 10.1093/brain/awv346. Epub 2015 Dec 8.

10.

Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease.

Harms AS, Thome AD, Yan Z, Schonhoff AM, Williams GP, Li X, Liu Y, Qin H, Benveniste EN, Standaert DG.

Exp Neurol. 2018 Feb;300:179-187. doi: 10.1016/j.expneurol.2017.11.010. Epub 2017 Nov 16.

11.

Targeted overexpression of human alpha-synuclein triggers microglial activation and an adaptive immune response in a mouse model of Parkinson disease.

Theodore S, Cao S, McLean PJ, Standaert DG.

J Neuropathol Exp Neurol. 2008 Dec;67(12):1149-58. doi: 10.1097/NEN.0b013e31818e5e99.

12.

Structural and Aggregation Properties of Alpha-Synuclein Linked to Phospholipase A2 Action.

Broersen K, Ruiperez V, Davletov B.

Protein Pept Lett. 2018;25(4):368-378. doi: 10.2174/0929866525666180326120052.

PMID:
29577851
13.

Microglial activation and antioxidant responses induced by the Parkinson's disease protein α-synuclein.

Béraud D, Hathaway HA, Trecki J, Chasovskikh S, Johnson DA, Johnson JA, Federoff HJ, Shimoji M, Mhyre TR, Maguire-Zeiss KA.

J Neuroimmune Pharmacol. 2013 Mar;8(1):94-117. doi: 10.1007/s11481-012-9401-0. Epub 2012 Oct 10.

14.

Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease.

Gardai SJ, Mao W, Schüle B, Babcock M, Schoebel S, Lorenzana C, Alexander J, Kim S, Glick H, Hilton K, Fitzgerald JK, Buttini M, Chiou SS, McConlogue L, Anderson JP, Schenk DB, Bard F, Langston JW, Yednock T, Johnston JA.

PLoS One. 2013 Aug 23;8(8):e71634. doi: 10.1371/journal.pone.0071634. eCollection 2013.

15.

Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease.

Zhang W, Wang T, Pei Z, Miller DS, Wu X, Block ML, Wilson B, Zhang W, Zhou Y, Hong JS, Zhang J.

FASEB J. 2005 Apr;19(6):533-42.

PMID:
15791003
16.

Alpha-synuclein activates BV2 microglia dependent on its aggregation state.

Hoffmann A, Ettle B, Bruno A, Kulinich A, Hoffmann AC, von Wittgenstein J, Winkler J, Xiang W, Schlachetzki JCM.

Biochem Biophys Res Commun. 2016 Oct 28;479(4):881-886. doi: 10.1016/j.bbrc.2016.09.109. Epub 2016 Sep 22.

PMID:
27666480
17.

α-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration.

Harms AS, Delic V, Thome AD, Bryant N, Liu Z, Chandra S, Jurkuvenaite A, West AB.

Acta Neuropathol Commun. 2017 Nov 21;5(1):85. doi: 10.1186/s40478-017-0494-9.

18.

Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?

Olanow CW, Brundin P.

Mov Disord. 2013 Jan;28(1):31-40. doi: 10.1002/mds.25373. Review.

PMID:
23390095
19.

The Peripheral Inflammatory Response to Alpha-Synuclein and Endotoxin in Parkinson's Disease.

White AJ, Wijeyekoon RS, Scott KM, Gunawardana NP, Hayat S, Solim IH, McMahon HT, Barker RA, Williams-Gray CH.

Front Neurol. 2018 Nov 20;9:946. doi: 10.3389/fneur.2018.00946. eCollection 2018.

20.

Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.

Febbraro F, Andersen KJ, Sanchez-Guajardo V, Tentillier N, Romero-Ramos M.

Exp Neurol. 2013 Sep;247:45-58. doi: 10.1016/j.expneurol.2013.03.017. Epub 2013 Mar 24.

PMID:
23531432

Supplemental Content

Support Center